Warning: session_start(): Cannot start session when headers already sent in /var/www/html/conference01/libs/common.php on line 4
KSMO 2021



Sep. 3 (Fri)

Plenary Lecture 3

Professor Joan S Brugge is a professor in the Department of Cell Biology at Harvard University and director of the Ludwig Center at the same university. The main research topic is the intracellular processes and signaling systems involved in tumorigenesis. Research on how oncogenes act in the early stages of the cancer process is also leading to the possibility of tumor surveillance. In addition, research on the mechanisms of response and resistance of cancer cells to drugs in breast cancer is being conducted, and several related important papers are being published. In this lecture, under the title of ‘Tumor heterogeneity and treatment resistance,’ important insights for tumor heterogeneity, one of the major mechanisms of drug resistance and strategies for overcoming drug resistance, will be explored.
Date & Time Sep. 3 (Fri), 09:00-09:40 Venue Room A
Chair TBD
Presentation
Detail
Tumor heterogeneity and treatment resistance
Joan S BRUGGE (Harvard Medical School, USA)

ASCO/KSMO Joint Symposium 2

Ladder of Cancer treatment : Precision medicine and Palliative care
Precision medicine and palliative care are two important pillars of modern cancer treatment. This session will cover the latest knowledge of immuno-oncology treatment as an adjuvant treatment and the direction of palliative care in each country.
Date & Time Sep. 3 (Fri), 10:00-11:30 Venue Room A
Chair
  • TBD
Presentation
Detail
  1. 1.Adjuvant treatment with IO : one size fits all?? : selection of patients who need adjuvant IO
    Rodabe N. Amaria (The University of Texas MD Anderson Cancer Center, USA)
  2. 2.Conducting clinical trials of adjuvant treatment with targeted therapy
    Yeon Hee PARK (Samsung Medical Center, Korea)
  3. 3.Incorporation of Palliative Care in ASCO
    Ishwaria Mohan Subbiah (The University of Texas MD Anderson Cancer Center, USA)
  4. 4.Introduction of Korean Academy of Supportive Care in Cancer
    Jung Hye KWON (Chungnam National University Sejong Hospital, Korea)

KOSRO/KSMO Joint Symposium

De-escalation/Escalation of radiotherapy
In the Joint Symposium of the Korean Society for Radiation Oncology (KOSRO) and Korean Society of Medical Oncology (KSMO), the topic of the year is the “De-escalation and Escalation of Radiotherapy.” Breast cancers and HPV-positive head & neck cancers will be the subject of de-escalation radiotherapy, while the treatment of esophageal cancers and lung cancers will be discussed from the viewpoint of escalation radiotherapy.
Date & Time Sep. 3(Fri), 10:00-11:30 Venue Room B
Chair
  • TBD
Presentation
Detail
  1. 1.De-escalation : breast cancer
    Yong Bae KIM (Yonsei University College of Medicine, Korea)
  2. 2.De-escalation : HPV+ oropharyngeal cancer
    Sue YOM (UCSF, USA)
  3. 3.Escalation : esophageal cancer
    Ken KATO (National Cancer Center Hospital, Japan)
  4. 4.Escalation: lung cancer
    Sung-Ja AHN (Chonnam National University Medical School, Korea)

SATELLITE SYMPOSIUM

Cardio-Oncology conference
Date & Time Sep. 3(Fri), 10:00-11:30 Venue Room C
Chair TBD
Presentation
Detail
  1. 1.Anti-cancer treatment induced cardiotoxicity and optimal surveillance strategy for oncologist
    Yun-Gyoo LEE (Kangbuk Samsung Hospital, Korea)
  2. 2.Screening and monitoring of cardiotoxicity
    Chi Young SHIM (Severance Hospital, Korea)
  3. 3.Management of cardiotoxicity
    Eun Kyoung KIM (Samsung Medical Center, Korea)
  4. 4.Real world of cardio-oncology clinic
    Peter Y. KIM (The University of Texas MD Anderson Cancer Center, USA)

Scientific Symposium 7

Recent advances in Hepatocellular carcinoma/Pancreas-Biliary Ca
After the long stagnation in new drug development for hepatobiliary and pancreatic cancers, very encouraging clinical research results have recently been emerging. This session is anticipated to provide an opportunity to update the latest knowledge of hepatobiliary and pancreatic cancer through world-renowned leaders in the clinical research for these tumor types.
Date & Time Sep. 3 (Fri), 12:40-14:00 Venue Room A
Chair TBD
Presentation
Detail
  1. 1.Emergence of immunotherapy in HCC: what's the future practice and next step for research?
    Ghassan ABOU-ALFA (MSKCC, USA)
  2. 2.Dawn of a new era for biliary tract cancer: targeted and immunotherapy
    Do-Youn OH (Seoul National University Hospital, Korea)
  3. 3.Beyond PARPi and novel therapy in pancreatic cancer
    Teresa MACARULLA (VHIO, Spain)

Scientific Symposium 3

Expanding indications of PARP inhibitors
The activity of PARP inhibitors in BRCA1/2-deficient cancers is the archetype of synthetic lethality, but the indications of PARP inhibitors are expanding rapidly. Current clinical indications include ovarian, breast, prostate, and pancreas cancers with various biomarkers and diagnostic tools. This session highlights the characteristics of the tumors sensitive to PARP inhibitors and renowned experts will share their perspectives.
Date & Time Sep. 3 (Fri), 12:40-14:00 Venue Room B
Chair
  • TBD
  • Presentation
    Detail
    1. 1.BRCA1/2 mutations, BRCAness, HRDness, and PARPness
      Kyung-Hun LEE (Seoul National University Hospital, Korea)
    2. 2.The Development of PARP inhibitors
      Mark J O'CONNOR (AstraZeneca, UK)
    3. 3.Clinical indications of PARP inhibitors
      Amit M. OZA (University of Toronto, Canada)
    4. 4.Mechanism of resistance and clinical implications
      Kyong Hwa PARK (Korea University Anam Hospital, Korea)

    Multidisciplinary Oncology Team Education Session 3

    Advances in toxicity management
    Date & Time Sep. 3 (Fri), 12:40-14:00 Venue Room C
    Chair TBD
    Presentation
    Detail
    1. 1.ILD management
      Byoung Soo KWON (Seoul National University Bundang Hospital, Korea)
    2. 2.Endocrine toxicity
      Hyemi KWON (Kangbuk Samsung Hospital, Korea)
    3. 3.Skin toxicity
      Chong Won CHOI (Seoul National University Bundang Hospital, Korea)
    4. 4.Radiation toxicity
      Jeong Il YU (Samsung Medical Center, Korea)

    KSSO/KSMO Joint Symposium

    Multimodality Treatment Strategy: Primary surgery in de novo stage IV breast cancer, and neoadjuvant chemotherapy followed by surgery in locally advanced pancreatic cancer
    A coordinated multidisciplinary approach is essential in the management of advanced cancer. In the KSSO/KSMO joint session, complicated issues in advanced breast and pancreatic cancer will be covered; surgical resection of the primary breast tumor in patients with stage IV breast cancer and neoadjuvant chemotherapy followed by surgery in locally advanced pancreatic cancer. Through this symposium, the perspectives from surgical and medical oncologists on each issue will be presented and shared for more successful treatment outcomes.
    Date & Time Sep. 3(Fri), 14:20-15:50 Venue Room A
    Chair
    • TBD
    Presentation
    Detail
    1. 1.Neoadjuvant chemotherapy followed by surgery in locally advanced pancreato-biliary cancer 
      Jin-Young JANG (Seoul National University Hospital, Korea)
    2. 2.Recent advances in neoadjuvant chemotherapy for locally advanced pancreato-biliary cancer
      Changhoon YOO (Asan Medical Center, Korea)
    3. 3.Primary breast surgery for newly diagnosed stage IV breast cancer patients
      So Youn JUNG (National Cancer Center, Korea)
    4. 4.How to manage stage IV breast cancer patients with oligometastasis
      Han Jo KIM (Soonchunhyang University Cheonan Hospital, Korea)

    KSP/KSMO Joint Symposium

    Tumor microenvironment and pathology
    The KSP/KSMO Joint Symposium will focus on tumor microenvironments in pathology, which are considered to be important in cancer treatment and molecular diagnosis. We will introduce an example of AI-based biomarker development, multiplex immunohistochemistry, secretome analysis of extracellular space and spatial NGS for tumor microenvironments.
    Date & Time Sep. 3(Fri), 14:20-15:50 Venue Room B
    Chair
    • TBD
    Presentation
    Detail
    1. 1.Whole-Slide Image Analysis Reveals Quantitative Landscape of Tumor-Immune Microenvironment in Colorectal Cancers
      Seung Yeon YOO (Asan Medical Center, Korea)
    2. 2.Immune cell analysis of microenvironment using multiplex IHC
      Yoonjin KWAK (Seoul National University Hospital, Korea)
    3. 3.Widespread multi-targeted therapy resistance via drug-induced secretome fucosylation
      Mark Borris D. ALDONZA (Seoul National University, Korea)
    4. 4.Parsing the tumour microenvironment of breast cancer using integrated single-cell and spatially-resolved multi-omics
      Alex SWARBRICK (Garvan Institute of Medical Research, Australia)

    Multidisciplinary Oncology Team Education Session 1

    Current strategies for maximizing the benefit of immunotherapy
    Date & Time Sep. 3 (Fri), 14:20-15:50 Venue Room C
    Chair TBD
    Presentation
    Detail
    1. 1.Strategy for maximizing the benefit of immunotherapy (clinical trials)
      Seung Hoon BEOM (Severance Hospital, Korea)
    2. 2.Practical biomarkers and timing of immunotherapy: is earlier immunotherapy better? (lesson from lung cancer treatment)
      Ji Hyun PARK (Konkuk Medical University Hospital, Korea)
    3. 3.Pseudoprogression vs. Hyperprogression after immunotherapy: real phenomenon vs. fiction
      Hong Jae CHON (Cha Bundang Medical Center, Korea)
    4. Discussion: Q & A

    Scientific Symposium 8

    Infection and cancer: HBV, HIV, HPV, CMV etc
    The relationship between infections and tumors has been actively studied in the past, but its importance has long been overlooked. In the so-called “era of immuno-oncology,” the relationship between infection and cancer is drawing attention again. This session will cover the impact of various bacterial and viral infections on cancers, tumor microenvironments, and immunotherapy - from preclinical to the latest clinical research findings.
    Date & Time Sep. 3 (Fri), 16:00-17:00 Venue Room A
    Chair TBD
    Presentation
    Detail
    1. 1.Bacterial infections and human cancer
      Thomas F. MEYER (Max Planck Institute for Infection Biology, Germany)
    2. 2.HBV Infection–Based HCC TME and immunotherapy
      Valerie Chew Suk PENG (Translational Immunology Institute (TII), Singapore)
    3. 3.Screening for early nasopharyngeal cancers by circulating Epstein-Barr virus DNA analysis
      KC Allen CHAN (The Chinese University of Hong Kong, HK)

    KSR/KSMO Joint Symposium

    State-of-the-art oncologic imaging analysis
    This session is a joint symposium with the Korean Society of Radiology (KSR). This year, we will deal with state-of-the-art imaging techniques and imaging analysis methods for medical oncology. The audience will have an opportunity to know the recent advances in the oncology imaging field, which include "evolution of cancer imaging for response and toxicity assessment," "emerging response evaluation strategies on immunotherapy” and "molecular imaging for tumor immune microenvironment.”
    Date & Time Sep. 3(Fri), 16:00-17:00 Venue Room B
    Chair
    • TBD
    Presentation
    Detail
    1. 1.Evolution of cancer imaging for response and toxicity assessment for targeted therapy
      Kyung Won KIM (Asan Medical Center, Korea)
    2. 2.Emerging strategies for RECISTing on immunotherapy
      Ho Yun LEE (Samsung Medical Center, Korea)
    3. 3.Molecular imaging biomarker for tumor immune microenvironment
      Hongyoon CHOI (Seoul National University Hospital, Korea)

    Multidisciplinary Oncology Team Education Session 2

    Targeted therapy : clinical effects and resistance
    Date & Time Sep. 3 (Fri), 16:00-17:00 Venue Room C
    Chair TBD
    Presentation
    Detail
    1. 1.Small Molecule TKIs (tyrosine kinase inhibitors)
      Jina YUN (Soon Chun Hyang University Hospital Bucheon, Korea)
    2. 2.Monoclonal Antibodies, ADCs
      Jae Ho JEONG (Asan Medical Center, Korea)
    3. 3.Others : Cell cycle inhibitors, Antiangiogenesis inhibitors
      Hyewon RYU (Chungnam National University, Korea)

    Plenary Lecture 4

    Professor Jean-Charles SORIA is a professor of oncology at the University of Paris-Saclay University. He is the general director of the Institute Gustave Roussy Cancer Center and head of the Phase I clinical trial program. His main research subjects are lung cancer, phase 1 clinical trials, biomarker research, and precision medicine. From 2017 to 2019, he served as a senior vice-president of R&D at AstraZeneca, taking the lead in the development of immunotherapy and cell therapy drugs. As a lead researcher, he has published important papers in major journals while participating in research related to the development of immuno-oncology drugs and new anti-cancer targeted therapies. In this meeting, a plenary lecture titled ‘Drug development in oncology: The revolution of the last 15 years’ will be presented and address comprehensive research achievements so far, providing a direction for the future development of new drugs.
    Date & Time Sep. 3 (Fri), 17:00-17:40 Venue Room A
    Chair TBD
    Presentation
    Detail
    Drug development in oncology: the revolution of the last 15 years
    Jean-Charles SORIA (Gustave Roussy Cancer Center, France)